Switch theme
Sign up to access all valuation multiples
Abbott India Ltd is a drug manufacturing company that offers products in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals. Its patient focus centers overwhelmingly on women's health and gastrointestine, gastroenterology, and hepatic care. Geographically, the majority of the company's revenue is generated in India.
1944
3.8K+
LTM Revenue $760M
LTM EBITDA $198M
$7.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Abbott India has a last 12-month revenue of $760M and a last 12-month EBITDA of $198M.
In the most recent fiscal year, Abbott India achieved revenue of $686M and an EBITDA of $200M.
Abbott India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Abbott India valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $627M | $686M | XXX | XXX | XXX |
| Gross Profit | $263M | $277M | XXX | XXX | XXX |
| Gross Margin | 42% | 40% | XXX | XXX | XXX |
| EBITDA | $159M | $200M | XXX | XXX | XXX |
| EBITDA Margin | 25% | 29% | XXX | XXX | XXX |
| Net Profit | $93.7M | $111M | XXX | XXX | XXX |
| Net Margin | 15% | 16% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 28, 2025, Abbott India's stock price is INR 29785 (or $349).
Abbott India has current market cap of INR 633B (or $7.4B), and EV of INR 615B (or $7.2B).
See Abbott India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.2B | $7.4B | XXX | XXX | XXX | XXX | $7.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 28, 2025, Abbott India has market cap of $7.4B and EV of $7.2B.
Abbott India's trades at 9.5x LTM EV/Revenue multiple, and 36.4x LTM EBITDA.
Analysts estimate Abbott India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Abbott India and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $7.2B | XXX | XXX | XXX |
| EV/Revenue | 9.8x | XXX | XXX | XXX |
| EV/EBITDA | 36.6x | XXX | XXX | XXX |
| P/E | 47.8x | XXX | XXX | XXX |
| P/E/Growth | 3.6x | XXX | XXX | XXX |
| EV/FCF | 56.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAbbott India's NTM/LTM revenue growth is 11%
Abbott India's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $37K for the same period.
Over next 12 months, Abbott India's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Abbott India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Abbott India and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 37% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $37K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 21% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Abbott India acquired XXX companies to date.
Last acquisition by Abbott India was XXXXXXXX, XXXXX XXXXX XXXXXX . Abbott India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Abbott India founded? | Abbott India was founded in 1944. |
| Where is Abbott India headquartered? | Abbott India is headquartered in India. |
| How many employees does Abbott India have? | As of today, Abbott India has 3.8K+ employees. |
| Is Abbott India publicy listed? | Yes, Abbott India is a public company listed on BOM. |
| What is the stock symbol of Abbott India? | Abbott India trades under 500488 ticker. |
| When did Abbott India go public? | Abbott India went public in 1992. |
| Who are competitors of Abbott India? | Similar companies to Abbott India include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Abbott India? | Abbott India's current market cap is $7.4B |
| What is the current revenue of Abbott India? | Abbott India's last 12-month revenue is $760M. |
| What is the current EBITDA of Abbott India? | Abbott India's last 12-month EBITDA is $198M. |
| What is the current EV/Revenue multiple of Abbott India? | Current revenue multiple of Abbott India is 9.5x. |
| What is the current EV/EBITDA multiple of Abbott India? | Current EBITDA multiple of Abbott India is 36.4x. |
| What is the current revenue growth of Abbott India? | Abbott India revenue growth between 2023 and 2024 was 9%. |
| Is Abbott India profitable? | Yes, Abbott India is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
